↓ Skip to main content

One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor: A Randomized Trial

Overview of attention for article published in JAMA: Journal of the American Medical Association, March 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • Good Attention Score compared to outputs of the same age and source (77th percentile)

Citations

dimensions_citation
839 Dimensions

Readers on

mendeley
337 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor: A Randomized Trial
Published in
JAMA: Journal of the American Medical Association, March 2012
DOI 10.1001/jama.2012.347
Pubmed ID
Authors

Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Jörg T. Hartmann, Daniel Pink, Jochen Schütte, Giuliano Ramadori, Peter Hohenberger, Justus Duyster, Salah-Eddin Al-Batran, Marcus Schlemmer, Sebastian Bauer, Eva Wardelmann, Maarit Sarlomo-Rikala, Bengt Nilsson, Harri Sihto, Odd R. Monge, Petri Bono, Raija Kallio, Aki Vehtari, Mika Leinonen, Thor Alvegård, Peter Reichardt

Abstract

Synthetic arteriovenous grafts, an important option for hemodialysis vascular access, are prone to recurrent stenosis and thrombosis. Supplementation with fish oils has theoretical appeal for preventing these outcomes.

X Demographics

X Demographics

The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 337 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 6 2%
Japan 2 <1%
Ecuador 1 <1%
United Kingdom 1 <1%
Honduras 1 <1%
Belgium 1 <1%
Luxembourg 1 <1%
Croatia 1 <1%
Unknown 323 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 72 21%
Other 51 15%
Student > Doctoral Student 34 10%
Student > Postgraduate 28 8%
Student > Ph. D. Student 25 7%
Other 74 22%
Unknown 53 16%
Readers by discipline Count As %
Medicine and Dentistry 216 64%
Agricultural and Biological Sciences 12 4%
Biochemistry, Genetics and Molecular Biology 11 3%
Pharmacology, Toxicology and Pharmaceutical Science 9 3%
Economics, Econometrics and Finance 5 1%
Other 18 5%
Unknown 66 20%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 22. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 June 2023.
All research outputs
#1,723,726
of 25,837,817 outputs
Outputs from JAMA: Journal of the American Medical Association
#11,604
of 36,763 outputs
Outputs of similar age
#9,370
of 175,239 outputs
Outputs of similar age from JAMA: Journal of the American Medical Association
#76
of 336 outputs
Altmetric has tracked 25,837,817 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 36,763 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 72.7. This one has gotten more attention than average, scoring higher than 68% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 175,239 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 336 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.